ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-EGFR Bispecific Antibody EPI-326

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by EpiBiologics.

Furthest: phase 1, since Mar 5, 20261 company-led study, 1 open or runningNext primary completion: Jul 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EpiBiologics11 open or runningphase 1since Mar 5, 2026Mar 5, 2026Jul 2029phase 1 · NCT07462377

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 5, 2026First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07462377 · 110 planned · United States, South Korea, Taiwan

Ahead

  1. Jul 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07462377

TargetBeta

EGFR →read by rule
“A humanized immunoglobulin G1 (IgG1) bispecific antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor (EGFR; HER1; ErbB1) and a degrader receptor localized in EGFR-driven tumors, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07462377Carcinoma, Non-Small-Cell Lung · United States, South Korea, Taiwan1RecruitingJul 2029110

How it is read

Names in the registry

  • “EPI-326”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.